CML Experts in Canada - Experts LMC au Canada

( Note: this list is not exhaustive) 
CML Experts in Quebec - Experts LMC au Quebec
                (Montreal - Quebec City - Sherbrooke)
Dr. Sarit Assouline
Dr. François Mercier
Dr. Lambert Busque
Dr. Josée Herbert
​Dr. Luigina Mollica
​Dr. Guy Sauvageau
Dr. Pierre Laneuville
​Dr. Jean-François Castilloux
​Dr. Vincent Éthier
Dr. Robert Delage
​Dr. Marc Lalancette
Hôpital Général Juif de Montréal
​Hôpital Général Juif de Montréal
Hôpital Maisonneuve-Rosemont (Montréal)
​Hôpital Maisonneuve-Rosemont (Montréal)
​Hôpital Maisonneuve-Rosemont (Montréal)
Hôpital Maisonneuve-Rosemont (Montréal)
​Hôpital Royal-Victoria (Montréal)
Centre hospitalier universitaire de Sherbrooke
Centre hospitalier universitaire de Sherbrooke
Hôpital de l’Enfant-Jésus   (Ville de Québec)  
CHU Pavillon Hôtel-Dieu de Québec  (Québec)
Vertical Divider
CML Experts in Ontario - Experts LMC en Ontario
Dr. Jeffrey H Lipton
Dr. Dennis Kim
​Dr. Isabelle Bence-Bruckler
​Princess Margaret Hospital (Toronto)
Princess Margaret Cancer Centre (Toronto)
Ottawa Hospital 
Vertical Divider
CML Experts in Alberta- Experts LMC en Alberta
​Dr. Mark Hnatiuk  ​          

CML Experts in British Columia- Experts LMC en Colombie Britannique

Dr. Donna L. Forrest
Dr.  John Shepherd
Dr. Kirk Schultz
Dr. David Sanford

CML Experts in Nova Scotia- Experts LMC en Nouvelle Écosse
Dr. Conrad Vincent Fernandez
CLINICAL TRIALS

Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study